Cepheid Inc. and the New Jersey Medical School have developed an assay system that integrates sample processing and real-time PCR diagnosis into a single, hands free process. During the successful completion of a phase I STTR application, we demonstrated that this system simultaneously detects the presence of Mycobacterium tuberculosis (TB) and diagnose rifampin resistance directly from clinical sputum samples. The assay uses an inexpensive plastic cartridge to collect sputum samples, concentrate the bacteria present in the sputum, perform high efficiency cell lysis and deliver inhibitor-free DNA into a PCR tube without user input. Detection of TB and rifampin resistance is also performed within the cartridge using a real-time PCR assay and a series of molecular beacon probes. The goal of this phase II STTR application is to further refine the sensitivity and robustness of the assay and to develop the commercial reagents, materials, software and protocols so that our system can be tested in larger-scale trials leading to its commercialization. This STTR will result in a desktop system that is sufficiently simple and robust to be performed anywhere with minimal training; and sufficiently sensitive and specific to be performed on patients with smear negative tuberculosis. Specifically we aim to: 1) Modify the assay to function in a new 6-color instrument, and further refine the assay using innovative strategies to increase its sensitivity, specificity and robustness. 2) Convert assay components and protocols into the appropriate format for clinical trials and subsequent commercialization by lyophilizing all reagents for factory packaging, and developing simple methods to load samples and buffers into the cartridge. 3) Perform pre-clinical testing to verify assay sensitivity, specificity and limits of detection and assess the effects of potential interfering substances. The system will then be retested using a large number of clinical sputum specimens. Finally, we will develop complete documentation on the assay including production, and development reports. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Technology Transfer (STTR) Grants - Phase II (R42)
Project #
2R42AI052523-02
Application #
7162387
Study Section
Special Emphasis Panel (ZRG1-IDM-M (11))
Program Officer
Jacobs, Gail G
Project Start
2002-08-15
Project End
2009-08-31
Budget Start
2006-09-01
Budget End
2007-08-31
Support Year
2
Fiscal Year
2006
Total Cost
$1,479,189
Indirect Cost
Name
Cepheid
Department
Type
DUNS #
956711444
City
Sunnyvale
State
CA
Country
United States
Zip Code
94089
Vadwai, Viral; Boehme, Catharina; Nabeta, Pamela et al. (2011) Xpert MTB/RIF: a new pillar in diagnosis of extrapulmonary tuberculosis? J Clin Microbiol 49:2540-5
Helb, Danica; Jones, Martin; Story, Elizabeth et al. (2010) Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol 48:229-37
Banada, Padmapriya P; Sivasubramani, Satheesh K; Blakemore, Robert et al. (2010) Containment of bioaerosol infection risk by the Xpert MTB/RIF assay and its applicability to point-of-care settings. J Clin Microbiol 48:3551-7
Boehme, Catharina C; Nabeta, Pamela; Hillemann, Doris et al. (2010) Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 363:1005-15
Blakemore, Robert; Story, Elizabeth; Helb, Danica et al. (2010) Evaluation of the analytical performance of the Xpert MTB/RIF assay. J Clin Microbiol 48:2495-501
Rodas, Juan D; Cairo, Cristiana; Djavani, Mahmoud et al. (2009) Circulating natural killer and gammadelta T cells decrease soon after infection of rhesus macaques with lymphocytic choriomeningitis virus. Mem Inst Oswaldo Cruz 104:583-91